Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial.

Study answer

What this study found

Melatonin improved both sleep and atopic dermatitis severity versus placebo, with no adverse events reported. SCORAD improved more with melatonin than placebo, with a between-group difference of -9.1 (-13.7 to -4.6; P < .001), and objective SCORAD showed a difference of -8.7 (-12.6 to -4.8; P < .001). Sleep-onset latency also decreased more with melatonin, with a between-group difference of -21.4 (-38.6 to -4.2; P = .02). Urinary 6-sulfatoxymelatonin increased significantly after melatonin versus placebo (P < .001), while total IgE and allergen-specific IgE did not differ.

Study & population

Randomized, placebo-controlled crossover clinical trial in children and adolescents aged 1 to 18 years with physician-diagnosed atopic dermatitis involving at least 5% of body surface area and sleep disturbance.

Intervention

Oral melatonin, 3 mg/day, taken at bedtime for 4 weeks, followed by a 2-week washout and crossover to the alternate treatment for another 4 weeks.

Key limitation

Single-center trial with a small sample and short treatment periods limits generalizability and precision.

View full study detailsView sourceOpen PDF

Original abstract